肺段切除与肺叶切除在临床T1cN0M0非小细胞肺癌中的结局比较
该单机构回顾性研究比较了临床T1cN0M0非小细胞肺癌患者接受肺段切除(90例)与肺叶切除(279例)的结局,发现两组在复发-free生存、总生存及主要并发症等方面均无显著差异,倾向性评分匹配分析结果一致,提示解剖性肺段切除可能不劣于肺叶切除,但需前瞻性随机试验验证。
要点
- 临床T1cN0M0非小细胞肺癌中,肺段切除与肺叶切除的5年无复发生存和总生存无显著差异。
- 两组主要并发症发生率、住院时间和30/90天死亡率均无统计学差异。
- 倾向性评分匹配分析显示总生存、无复发生存和复发时间的风险比无显著差异。
核心结论
- 在临床T1cN0M0非小细胞肺癌中,解剖性肺段切除与肺叶切除在5年无复发生存和总生存方面无显著差异。
研究设计与样本
- 单机构回顾性研究,纳入2003年1月1日至2016年12月31日期间接受肺段切除(90例)或肺叶切除(279例)的T1c非小细胞肺癌患者。
- 采用单变量、多变量和倾向性评分加权分析,终点包括无复发生存、总生存和复发时间。
临床怎么用
- 对于临床T1cN0M0非小细胞肺癌,解剖性肺段切除可作为肺叶切除的潜在替代选择,但需个体化评估。
- 需进一步前瞻性随机试验验证将解剖性肺段切除推广至所有AJCC第8版IA期非小细胞肺癌的可行性。
局限性
- 本研究为单机构回顾性研究,可能存在选择偏倚。
- 样本量有限,肺段切除组仅90例。
- 需要前瞻性随机试验 corroborate 结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We hypothesize that segmentectomy is associated with similar recurrence-free and overall survival when compared with lobectomy in the setting of patients with clinical T1cN0M0 non-small cell lung cancer (NSCLC; >2-3 cm), as defined by the American Joint Committee on Cancer 8th edition staging system. METHODS: We performed a single-institution retrospective study identifying patients undergoing segmentectomy (90) versus lobectomy (279) for T1c NSCLC from January 1, 2003, to December 31, 2016. Univariate, multivariable, and propensity score-weighted analyses were performed to analyze the following endpoints: freedom from recurrence, overall survival, and time to recurrence. RESULTS: Patients undergoing segmentectomy were older than patients undergoing lobectomy (71.5 vs 68.8, respectively, P = .02). There were no differences in incidence of major complications (12.4% vs 11.7%, P = .85), hospital length of stay (6.2 vs 7 days, P = .19), and mortality at 30 (1.1% vs 1.7%, P = 1) and 90 days (2.2% vs 2.3%, P = 1). In addition, there were no statistical differences in locoregional (12.2% vs 8.6%, P = .408), distant (11.1% vs 13.9%, P = .716), or overall recurrence (23.3% vs 22.5%, P = 1), as well as 5-year freedom from recurrence (68.6% vs 75.8%, P = .5) or 5-year survival (57.8% vs 61.0%, P = .9). Propensity score-matched analysis found no differences in overall survival (hazard ratio [HR], 1.034; P = .764), recurrence-free survival (HR, 1.168; P = .1391), or time to recurrence (HR, 1.053; P = .7462). CONCLUSIONS: In the setting of clinical T1cN0M0 NSCLC, anatomic segmentectomy was not associated with significant differences in recurrence-free or overall survival at 5 years. Further prospective randomized trials are needed to corroborate the expansion of the role of anatomic segmentectomy to all American Joint Committee on Cancer 8th Edition Stage 1A NSCLC.
引用
- Chan EG, Chan PG, Mazur SN, et al. Outcomes with segmentectomy versus lobectomy in patients with clinical T1cN0M0 non-small cell lung cancer. J Thorac Cardiovasc Surg. 2020. PMID: 32331817. doi:10.1016/j.jtcvs.2020.03.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。